Dysregulation of SREBPs has been implicated in various metabolic disorders, including obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD). Overactivation of SREBPs can lead to excessive lipid accumulation in tissues, contributing to insulin resistance and hepatic steatosis. Targeting the SREBP pathway is being explored as a potential therapeutic strategy for these conditions.
